Satsuma Pharmaceuticals Inc. [NASDAQ: STSA] The stock went on an uptrend that gained over 10.40% on Monday, showing a one-week price gain of over 5.61%. The company reported on November 14, 2022 that Satsuma Pharmaceuticals announced topline results from the SUMMIT Phase 3 trial of STS101 for the acute treatment of migraine.
China Can’t Stop US$0.25 Of Stock From Mining The Ultra-Rare Metal
Here’s a tiny company—trading at an unheard-of below 25-cents per share—that is developing one of the largest and highest-quality REE deposits in all of North America…and the Chinese are all about it. Can’t do anything! It’s early stages… and that’s great news for individual investors like you who have the foresight to act decisively on an emerging megatrend that is already being measured in the tens of billions of dollars.
Just click here and the name and trading symbol is yours.
In the past 12 months, STSA stock declined -86.71%. One Year Satsuma Pharmaceuticals Inc. The stock forecast points to a possible upside of 68.0. The Average Equity Rating for STSA stock is currently 2.30, which is trading closer to the bullish pattern in the stock market.
The market cap for the stock reached $22.63 million, with 31.86 million shares outstanding and 27.93 million shares in the current float. Compared to the average trading volume of 621.60K shares, the STSA stock reached a trading volume of 4702434 shares in the most recent trading day, which is why market watchdogs consider the stock active.
Guru’s Opinion on Satsuma Pharmaceuticals Inc. [STSA],
Based on careful and fact-backed analyzes by Wall Street experts, the current consensus on the target price for STSA shares is $2.25 per share. Target prices and analysis on the performance of stocks are usually carefully studied by market experts, and the current Wall Street consensus on STSA stock is a recommendation at 2.30. This rating represents a strong buy recommendation on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 indicates hold and 2 indicates buy.
SVB Leerink, in line with its previous recommendation on October 10, 2022, has maintained its view on the stock as Outperform, Satsuma Pharmaceuticals Inc. An estimate has been made for the shares of Rs. While these analysts kept the previous recommendation, Ladenberg Thalman raised its target price to buy. The new note on price target was issued on August 31, 2022, which represents the official price target for Satsuma Pharmaceuticals Inc stock. Earlier, there was another increase in the target price from $7 to $15, while Mizuho maintained a Buy rating on STSA stock.
Satsuma Pharmaceuticals Inc. The Average True Range (ATR) is set at 0.46. The Price to Book ratio for the previous quarter was 0.33, the Price to Cash per Share for the corresponding quarter was set at 2.05.
STSA Stock Performance Analysis:
Satsuma Pharmaceuticals Inc. [STSA] At the end of last week there was an increase in the green zone, an increase in a positive trend and a gain of 5.61. With this latest performance, STSA shares are down -86.81% in the last four-week period, as well as -77.58% in the last 6 months – referring to a -86.71% fall in the last year of trading. Not there.
Overbought and oversold stocks can be easily detected with the Relative Strength Index (RSI), where an RSI result of over 70 will result in overbought, and any rate below 30 will indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STSA stock for the past two-week period is set at 14.02, with the RSI for the last single at 9.16, and the three-week RSI for Satsuma Pharmaceuticals Inc. is set at 19.48. [STSA], The current moving average for the last 50 days of trade of this stock is 5.0939, while it was recorded at 0.6449 for the last one week of trade and 4.5337 for the last 200 days.
Satsuma Pharmaceuticals Inc. Insight into the fundamentals:
The Return on Equity for this stock decreased to -59.06 while the Return on Assets stood at -53.62.
Satsuma Pharmaceuticals Inc. Equally intriguing is its liquidity data, with a quick ratio of 10.10 and a current ratio set at 10.10.
Satsuma Pharmaceuticals Inc. [STSA] internal status statement
Institutional investors currently hold approximately $18 million, or 74.40% of STSA stock, in their hands. The top three institutional holders of STSA shares are: RA CAPITAL MANAGEMENT, LP with ownership of 5,914,252, which is about 0% of the company’s market cap and about 9.98% of total institutional ownership; Commodore Capital LP holds 3,711,286 shares of STSA stock with an estimated value of $2.67 million in STSA stock shares; and NEA Management Company, LLC, with $2.26 million in STSA stock currently owned with approximately 0% of the company’s market capitalization.
Satsuma Pharmaceuticals Inc. Shares positions held by institutional investors increased at the end of November and at the time of the November reporting period, where 24 institutional holders increased their positions in Satsuma Pharmaceuticals Inc. [NASDAQ:STSA] By approximately 2,625,067 shares. Additionally, 15 investors reduced positions by approximately 922,428 shares, while 7 investors maintained positions by approximately 20,934,981 shares. As per the latest SEC report filing, the mentioned changes put the institutional holdings at 24,482,476 shares. There were 14 new institutional investments in STSA stock for a total of 2,160,309 shares, while 4 institutional investors sold 220,380 shares during the same period.